As stated by the NCCN consensus panel for prostate cancer, “Because of the increased sensitivity and specificity of PSMA-PET tracers for detecting micrometastatic disease compared to conventional imaging (CT, MRI) at both initial staging and biochemical recurrence, the Panel does not feel that conventional imaging is a necessary prerequisite to PSMA-PET and that PSMA- PET-CT or PSMA-PET/MRI can serve as an equally effective, if not more effective front-line imaging tool for these patients” [84]. The gene discussed is FOLH1; the disease is Familial prostate cancer.